Systemic inflammation and mortality in chronic obstructive pulmonary disease

Canadian Journal of Physiology and Pharmacology

Volumn 85, Issue 1, 2007, Pages 141-147

  Sin, Don D ^a   Man, S F Paul ^a  

^a ST PAUL S HOSPITAL   (Canada)

Author keywords

COPD; Mortality; Review; Systemic inflammation

Indexed keywords

C REACTIVE PROTEIN; BIOLOGICAL MARKER;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; HUMAN; INFLAMMATION; MORTALITY; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; RABBIT; SHORT SURVEY; ANIMAL; BLOOD; CARDIOVASCULAR DISEASE; INCIDENCE; METABOLISM; NEOPLASM; PREDICTION AND FORECASTING; REVIEW; RISK ASSESSMENT; RISK FACTOR; TIME;

ANIMALS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; HUMANS; INCIDENCE; INFLAMMATION; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 34250817009     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y06-093     Document Type: Short Survey

References (37)

1. Anthonisen, N.R., Connett, J.E., Kiley, P., Altose, M.D., Bailey, W.C., Buist, A.S., et al. 1994. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA, 272: 1497-1505. doi:10.1001/jama.272.19.1497.
2. Anthonisen, N.R., Connett, J.E., Enright, P.L., and Manfreda, J., and Lung Health Study Research Group. 2002. Hospitalizations and mortality in the Lung Health Study. Am. J. Respir. Crit. Care Med. 166: 333-339. doi:10.1164/rccm.2110093.
3. Anthonisen, N.R., Skeans, M.A., Wise, R.A., Manfreda, J., Kanner, R.E., and Connett, J.E., and Lung Health Study Research Group. 2005. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 142: 233-239.
4. Camilli, A.E., Robbins, D.R., and Lebowitz, M.D. 1991. Death certificate reporting of confirmed airways obstructive disease. Am. J. Epidemiol. 133: 795-800.
5. Chapman, R.S., He, X., Blair, A.E., and Lan, Q. 2005. Improvement in household stoves and risk of chronic obstructive pulmonary disease in Xuanwei, China: retrospective cohort study. BMJ, 331: 1050. doi:10.1136/bmj.38628. 676088.55.
6. Curkendall, S.M., DeLuise, C., Jones, J.K., Lanes, S., Stang, M.R., Goehring, E., Jr., and She, D. 2006. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann. Epidemiol. 16: 63-70. doi:10.1016/j. annepidem.2005.04.008.
7. Cybulsky, M.I., Iiyama, K., Li, H., Zhu, S., Chen, M., Iiyama, M., et al. 2001. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J. Clin. Invest. 107: 1255-1262.
8. Danesh, J., Collins, R., Appleby, P., and Peto, R. 1998. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA, 279: 1477-1482. doi:10.1001/jama.279.18.1477.
9. Danesh, J., Lewington, S., Thompson, S.G., Lowe, G.D., Collins, R., Kostis, J.B., et al. 2005. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA, 294: 1799-1809.
10. Danesh, J., Whincup, P., Walker, M., Lennon, L., Thomson, A., Appleby, P., Gallimore, J.R., and Pepys, M.B. 2000. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ, 321: 199-204. doi:10.1136/bmj.321.7255.199.
11. Fabbri, L.M., and Hurd, S.S., and GOLD Scientific Committee. 2003. Global strategy for the diagnosis, management and prevention of COPD: 2003 update. Eur. Respir. J. 22: 1-2. doi:10.1183/09031936.03.00063703.
12. Fukushima, R., Alexander, J.W., Gianotti, L., and Ogle, C.K. 1994. Isolated pulmonary infection acts as a source of systemic tumor necrosis factor. Crit. Care Med. 22: 114-120.
13. Gan, W.Q., Man, S.F., Senthilselvan, A., and Sin, D.D. 2004. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a metaanalysis. Thorax, 59: 574-580. doi:10.1136/thx.2003.019588.
14. Gross, C.P., Anderson, G.F., and Powe, N.R. 1999. The relation between funding by the National Institutes of Health and the burden of disease. N. Engl. J. Med. 340: 1881-1887. doi:10.1056/NEJM199906173402406.
15. Hogg, J.C. 2004. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet, 364: 709-721. doi:10.1016/S0140- 6736(04)16900-6.
16. Hogg, J.C., Chu, F., Utokaparch, S., Woods, R., Elliott, W.M., Buzatu, L., et al. 2004. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 350: 2645-2653. doi:10.1056/ NEJMoa032158.
17. Hogg, J.C., Macklem, P.T., and Thurlbeck, W.M. 1968. Site and nature of airway obstruction in chronic obstructive lung disease. N. Engl. J. Med. 278: 1355-1360.
18. Hurst, J.R., Perera, W.R., Wilkinson, T.M., Donaldson, G.C., and Wedzicha, J.A. 2006. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 173: 71-78. doi:10.1164/rccm.200505-704OC.
19. Jemal, A., Ward, E., Hao, Y., and Thun, M. 2005. Trends in the leading causes of death in the United States, 1970-2002. JAMA, 294: 1255-1259. doi:10.1001/jama.294.10.1255.
20. Jousilahti, P., Vartiainen, E., Tuomilehto, J., and Puska, P. 1996. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet, 348: 567-572. doi:10.1016/S0140-6736(96)02374-4.
21. Koenig, W., Sund, M., Frohlich, M., Fischer, H.G., Lowel, H., Doring, A., Hutchinson, W.L., and Pepys, M.B. 1999. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation, 99: 237-242.
22. Man, S.F., Connett, J.E., Anthonisen, N.R., Wise, R.A., Tashkin, D.P., and Sin, D.D. 2006. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax, 61: 849-853. doi.10.1136/thx. 2006.059808.
23. McGarvey, L.P., John, M., Anderson, J.A., Zvarich, M.T., and Wise, R.A. 2007. Ascertainment of cause-specific mortality in COPD - operations of the TORCH Clinical Endpoint Committee. Thorax, In Press [Epub ahead of print]. doi:10.1136/thx.2006.072348.
24. Miolla, M. 1994. The cost of chronic disease in Canada. Available from http://www.gpiatlantic.org/pdf/health/chroniccanada.pdf.
25. Mukae, H., Hogg, J.C., English, D., Vincent, R., and van Eeden, S.F. 2000. Phagocytosis of particulate air pollutants by human alveolar macrophages stimulates the bone marrow. Am. J. Physiol. Lung Cell. Mol. Physiol. 279: L924-L931.
26. Murray, C.J., and Lopez, A.D. 1997. Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: global Burden of Disease Study. Lancet, 349: 1347-1352. doi:10.1016/S0140-6736(96)07494-6.
27. Niewoehner, D.E., Kleinerman, J., and Rice, D.B. 1974. Pathologic changes in the peripheral airways of young cigarette smokers. N. Engl. J. Med. 291: 755-758.
28. Pradhan, A.D., Manson, J.E., Rifai, N., Buring, J.E., and Ridker, P.M. 2001. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA, 286: 327-334. doi:10.1001/jama.286.3.327.
29. Ridker, P.M., Hennekens, C.H., Buring, J.E., and Rifai, N. 2000. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342: 836-843. doi:10.1056/NEJM200003233421202.
30. Ross, R. 1999. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340: 115-126. doi:10.1056/NEJM199901143400207.
31. Shankar, A., Wang, J.J., Rochtchina, E., Yu, M.C., Kefford, R., and Mitchell, P. 2006. Association between circulating white blood cell count and cancer mortality: a population-based cohort study. Arch. Intern. Med. 166: 188-194. doi:10.1001/archinte.166.2.188.
32. Sidney, S., Sorel, M., Quesenberry, C.P., Jr., DeLuise, C., Lane, S., and Eisner, M.D. 2005. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest, 128: 2068-2075. doi:10.1378/chest.128.4.2068.
33. Sin, D.D., and Man, S.F. 2003. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation, 107: 1514-1519. doi:10.1161/01.CIR.0000056767.69054.B3.
34. Sin, D.D., McAlister, F.A., Man, S.F., and Anthonisen, N.R. 2003. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA, 290: 2301-2312. doi:10.1001/jama.290.17.2301.
35. Suwa, T., Hogg, J.C., Quinlan, K.B., Ohgami, A., Vincent, R., and van Eeden, S.F. 2002. Particulate air pollution induces progression of atherosclerosis. J. Am. Coll. Cardiol. 39: 935-942. doi:10.1016/S0735- 1097(02)01715-1.
36. Terashima, T., Wiggs, B., English, D., Hogg, J.C., and van Eeden, S.F. 1997. Phagocytosis of small carbon particles (PM10) by alveolar macrophages stimulates the release of polymorphonuclear leukocytes from bone marrow. Am. J. Respir. Crit. Care Med. 155: 1441-1447.
37. Yasojima, K., Schwab, C., McGeer, E.G., and McGeer, P.L. 2000. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res. 887: 80-89. doi:10.1016/S0006-8993(00)02970-X.